Bremelanotide, catalogued as PT-141, is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors, working principally at the melanocortin-4 receptor (MC4R) in the central nervous system rather than on the vasculature. That central mode of action is the defining fact of the molecule: it separates bremelanotide from peripheral vasoactive drugs such as PDE5 inhibitors, and it is the reason both its intended effect and its side effects trace back to melanocortin signaling in the brain. It carries a defined FDA approval in the United States, which sets the regulated product apart from the same sequence sold as a research chemical.
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that activates central melanocortin-4 receptors in the hypothalamus, a mechanism distinct from the peripheral vascular action of PDE5 inhibitors.
Bremelanotide is a cyclic seven-residue peptide built around the conserved His-Phe-Arg-Trp melanocortin pharmacophore found in the natural ligand alpha-melanocyte-stimulating hormone. A lactam bridge between an aspartate and a lysine side chain closes the ring and locks the active motif into the conformation the receptor prefers, while an acetylated N-terminus and a norleucine substitution give the molecule more resistance to enzymatic breakdown than the linear native peptide.
Bremelanotide has the molecular formula C50H68N14O10 and a molecular weight of roughly 1025 daltons, and its lactam-bridged His-D-Phe-Arg-Trp ring is the feature that rigidifies the active motif and resists proteolysis.
The melanocortin system is a family of five G protein-coupled receptors, MC1R through MC5R, that respond to peptides cleaved from proopiomelanocortin and signal mainly through the Gs protein to raise intracellular cyclic AMP. Bremelanotide is a nonselective agonist across this family but engages MC4R and MC1R most strongly: MC4R is the therapeutically meaningful target in the brain, while the MC1R activity is a legacy of the molecule's tanning-peptide ancestry and accounts for its pigmentary effects rather than any central benefit.
| Receptor | Main location | Documented role |
|---|---|---|
| MC1R | Melanocytes | Pigmentation; source of the off-target skin effects |
| MC2R | Adrenal cortex | Cortisol release |
| MC3R / MC4R | Central nervous system | Energy balance, autonomic and sexual pathways |
| MC5R | Exocrine glands | Glandular secretion |
Bremelanotide is a nonselective melanocortin agonist that engages MC4R and MC1R most strongly, with MC4R serving as the central therapeutic target and MC1R driving its pigmentary side effects.
Once bremelanotide reaches melanocortin-dense regions of the brain, it binds MC4R on neurons that integrate appetitive, autonomic, and neuroendocrine signals, and raising cyclic AMP inside those cells shifts their output. This is not a blood-flow effect; it recruits downstream neurotransmitter circuitry, with dopaminergic signaling in particular implicated as the relay, which is why the response builds gradually rather than being locked to a local tissue trigger.
Bremelanotide produces its effect by raising cyclic AMP in MC4R-expressing hypothalamic neurons and recruiting dopaminergic circuitry, a centrally mediated cascade that also couples to autonomic outflow and raises blood pressure.
Melanotan II was engineered as a superpotent analog of alpha-MSH meant to drive skin tanning without ultraviolet exposure. During its early human study, investigators recorded a pronounced secondary effect unrelated to pigmentation, and that observation pivoted a strand of development toward an entirely different therapeutic direction. Bremelanotide emerged from that pivot as the C-terminally deamidated form of Melanotan II, a single backbone change that trims the pigmentary drive while keeping the melanocortin agonism behind the newly prized central effect.
PT-141 (bremelanotide) is the C-terminally deamidated form of the tanning peptide Melanotan II, a single backbone change that preserves melanocortin agonism while trimming the pigmentary drive and makes it a separate molecular entity.
Because it is a peptide of roughly a thousand daltons, bremelanotide is broken down by gastrointestinal proteases and first-pass metabolism before it can act, so the published record describes parenteral injection rather than oral dosing. Subcutaneous administration is the route carried into approved use, with intranasal delivery explored earlier in development and then set aside. Its systemic exposure is brief, a trait the literature ties to episodic, on-demand use rather than a standing daily regimen.
Bremelanotide is administered by subcutaneous injection, reaches peak plasma concentration about an hour after dosing, and clears with an elimination half-life of a few hours through peptide hydrolysis rather than CYP450 metabolism, so it does not accumulate with intermittent use.
The two mechanisms sit at opposite ends of the body and act on entirely different molecular targets. A PDE5 inhibitor works peripherally, blocking phosphodiesterase type 5 so that cyclic GMP accumulates in vascular smooth muscle and local blood flow rises, an effect that depends on an existing nitric oxide trigger. A melanocortin agonist such as bremelanotide instead acts centrally, activating MC4R neurons and raising cyclic AMP to modulate neural circuitry, so its response is slower and not tied to a local vascular trigger.
| Criteria | Melanocortin agonist (bremelanotide) | PDE5 inhibitor |
|---|---|---|
| Site of action | Central: MC4R neurons in the brain | Peripheral: vascular smooth muscle |
| Second messenger | Raises cyclic AMP | Raises cyclic GMP |
| Trigger dependence | Upstream central signaling | Requires an existing nitric oxide cascade |
| Onset | Slower, diffusely mediated | Quicker, coupled to local blood flow |
| Typical adverse effects | Nausea, transient blood-pressure rise | Flushing, headache, nasal congestion |
Bremelanotide acts centrally on MC4R neurons through cyclic AMP while PDE5 inhibitors act peripherally on vascular smooth muscle through cyclic GMP, which makes the two mechanisms complementary in concept but not interchangeable in action.
Bremelanotide holds a formal FDA approval in the United States, cleared in 2019 as a prescription therapy delivered by subcutaneous autoinjector for a narrowly defined patient population and condition. The labeling carries meaningful restrictions rather than an open-ended use profile: because central melanocortin activation raises blood pressure, the prescribing information advises against use in uncontrolled hypertension or established cardiovascular disease and caps the number of doses within a set time window.
Bremelanotide received FDA approval in the United States in 2019 as a prescription subcutaneous autoinjector for a narrowly defined indication, with labeling that restricts use in uncontrolled hypertension and cardiovascular disease and caps dosing frequency.
The root of much of bremelanotide's side-effect profile is that it is a broad-spectrum melanocortin agonist rather than a clean MC4R-selective compound. Its meaningful activity at MC1R produces the dermatologic effects seen with dosing, and its reach into autonomic pathways drives the most common tolerability complaints, nausea and flushing, along with a transient rise in blood pressure. Because these effects scale with exposure, the published record reports most as dose-related, which is the reason the labeling restricts how much and how often the peptide is given.
Bremelanotide's lack of MC4R selectivity, particularly its activity at MC1R, produces dose-related pigmentary changes, nausea, flushing, and transient blood-pressure elevation, which is why its labeling caps dosing frequency.
Educational use only. This article describes what the published scientific and clinical literature reports about PT-141 (bremelanotide). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
